ArticleBone marrow transplantation2023

Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial.

Zhitao Ying et al.PubMed ↗Publisher ↗

No numbers read from the abstract.